Citi initiated coverage of Axsome Therapeutics with a Buy rating and $125 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
- Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
- Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
- Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
- Axsome Therapeutics price target lowered to $90 from $100 at Mizuho